The United States Patent and Trademark Office (USPTO) has granted patent US12583871B2 to Merck Sharp & Dohme LLC. This patent covers novel compounds identified as PRMT5 inhibitors, along with their pharmaceutically acceptable salts, esters, and prodrugs. The invention also includes methods for synthesizing these compounds, pharmaceutical compositions containing them, and their therapeutic applications for treating cancer, sickle cell disease, and hereditary persistence of foetal hemoglobin (HPFH) mutations.

This patent grant signifies a new intellectual property asset for Merck Sharp & Dohme in the area of oncology and genetic disorders. While this is a patent grant and not a regulatory rule imposing direct compliance obligations on other entities, it highlights a specific area of innovation and potential future drug development. Companies operating in the pharmaceutical sector, particularly those involved in developing treatments for cancer or blood disorders, should be aware of this granted patent as it may impact their own research and development strategies or potential licensing opportunities.